ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
2,1,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
3,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
3,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
3,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
4,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
4,2,Myalgia,Muscle pains,Muscle disorders,Musc,N
4,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
5,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
5,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
6,1,Bleeding time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
7,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
8,1,Peyronie's disease,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
9,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
10,1,Headache,Headaches NEC,Headaches,Nerv,N
10,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
11,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
12,1,Headache,Headaches NEC,Headaches,Nerv,N
12,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
13,1,Ataxia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
13,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
13,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
14,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
14,2,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
15,1,Biliary colic,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
15,2,Withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
16,1,Biliary colic,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
16,2,Withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
17,1,Biliary colic,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
17,2,Withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
18,1,Biliary colic,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
18,2,Withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
19,1,Polyuria,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
19,2,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
20,1,Biliary colic,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
20,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
21,1,Biliary colic,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
21,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
22,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
23,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
24,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
25,1,Biliary colic,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
26,1,Biliary colic,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
26,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
27,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
28,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
29,1,Parotitis,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
30,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
30,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
30,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
31,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
31,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
32,1,Cholecystitis chronic,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
32,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
33,1,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
34,1,Exfoliative rash,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
35,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
35,2,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
35,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
35,4,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
36,1,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
37,1,Bile duct cancer,Bile duct neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
37,2,Pancreatic carcinoma,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
38,1,Behaviour disorder,Abnormal behaviour NEC,Psychiatric and behavioural symptoms NEC,Psych,N
38,2,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
39,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
39,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
39,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
40,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
41,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
42,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
42,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
42,3,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
43,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
44,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
44,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
44,3,Headache,Headaches NEC,Headaches,Nerv,N
44,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
44,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
45,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
46,1,Anosmia,Olfactory nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
47,1,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
47,2,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
48,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
48,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
49,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
49,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
50,1,Large intestinal obstruction,Large intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
50,2,Volvulus,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
51,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
51,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
52,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
52,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
53,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
54,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
54,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
54,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
54,4,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
54,5,Headache,Headaches NEC,Headaches,Nerv,N
54,6,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
54,7,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
54,8,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
55,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
56,1,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
56,2,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
57,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
58,1,Ichthyosis acquired,Ichthyoses,Cornification and dystrophic skin disorders,Skin,N
58,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
59,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
60,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
60,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
61,1,Headache,Headaches NEC,Headaches,Nerv,N
62,1,Parotid gland enlargement,Salivary gland enlargements,Salivary gland conditions,Gastr,N
63,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
63,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
64,1,Skin mass,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
65,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
65,2,Hypoalbuminaemia,Protein metabolism disorders NEC,Protein and amino acid metabolism disorders NEC,Metab,N
65,3,Normochromic normocytic anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
65,4,Skin necrosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
66,1,Headache,Headaches NEC,Headaches,Nerv,N
67,1,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
67,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
67,3,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
68,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
68,2,Completed suicide,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,Y
68,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
69,1,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
70,1,Sudden death,Death and sudden death,Fatal outcomes,Genrl,Y
71,1,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
71,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
72,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
72,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
73,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
74,1,Depressed level of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
74,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
75,1,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
75,2,Peptic ulcer perforation,Peptic ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
76,1,Parotid gland enlargement,Salivary gland enlargements,Salivary gland conditions,Gastr,N
76,2,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
77,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
77,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
77,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
78,1,Parotitis,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
79,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
80,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
80,2,Renal papillary necrosis,Renal vascular and ischaemic conditions,Renal disorders (excl nephropathies),Renal,N
81,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
82,1,Drug withdrawal headache,Headaches NEC,Headaches,Nerv,N
82,2,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
83,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
84,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
85,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
85,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
86,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
87,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
88,1,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
89,1,Rash vesicular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
90,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
90,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
90,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
91,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
91,2,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
91,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
92,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
93,1,Photosensitivity reaction,Photosensitivity and photodermatosis conditions,Epidermal and dermal conditions,Skin,N
94,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
94,2,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
94,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
94,4,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
95,1,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
96,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
97,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
97,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
97,3,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
97,4,Seborrhoea,Sebaceous gland disorders,Skin appendage conditions,Skin,N
98,1,Cortisol decreased,Adrenal cortex tests,Endocrine investigations (incl sex hormones),Inv,N
98,2,Poor feeding infant,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
99,1,Cholecystitis acute,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
99,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
100,1,Headache,Headaches NEC,Headaches,Nerv,N
101,1,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
102,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
103,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
103,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
103,3,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
103,4,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
103,5,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
103,6,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
103,7,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
103,8,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
103,9,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
103,10,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
103,11,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
103,12,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
104,1,Breast tenderness,Breast signs and symptoms,Breast disorders,Repro,N
105,1,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,N
105,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
105,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
105,4,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
105,5,Ketonuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
105,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
105,7,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
106,1,Aspiration,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,Y
107,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
107,2,Ovarian cancer,Ovarian neoplasms malignant (excl germ cell),Reproductive neoplasms female malignant and unspecified,Neopl,N
108,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
108,2,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
109,1,Blood creatine phosphokinase increased,Skeletal and cardiac muscle analyses,Enzyme investigations NEC,Inv,N
109,2,Myositis,Muscle infections and inflammations,Muscle disorders,Musc,N
110,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
111,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
111,2,Migraine,Migraine headaches,Headaches,Nerv,N
112,1,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
113,1,Cholestasis,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
113,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
114,1,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
115,1,Thyroid function test abnormal,Thyroid analyses,Endocrine investigations (incl sex hormones),Inv,N
116,1,Cholecystitis acute,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
116,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
116,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
116,4,Eructation,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
116,5,Insulin-like growth factor increased,Endocrine analyses and imaging NEC,Endocrine investigations (incl sex hormones),Inv,N
116,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
117,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
117,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
117,3,Eructation,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
117,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
118,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
118,2,Blood lactic acid increased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
118,3,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
118,4,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
118,5,Necrotising colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
118,6,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
118,7,Pneumatosis intestinalis,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
118,8,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
118,9,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
119,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
119,2,Femur fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
119,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
119,4,Thyroglobulin increased,Thyroid analyses,Endocrine investigations (incl sex hormones),Inv,N
120,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
120,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
121,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
122,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
123,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
124,1,Parotitis,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
125,1,Impaired healing,Healing abnormal NEC,Tissue disorders NEC,Genrl,N
125,2,Malabsorption,Malabsorption syndromes,Malabsorption conditions,Gastr,N
126,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
126,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
126,3,Polydipsia,Fluid intake increased,Electrolyte and fluid balance conditions,Metab,N
126,4,Polyuria,Urinary tract signs and symptoms NEC,Urinary tract signs and symptoms,Renal,N
126,5,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
127,1,Apnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
127,2,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
127,3,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
128,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
129,1,Asthma,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
130,1,Device failure,Device issues NEC,Device issues,Prod,N
131,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
132,1,Decubitus ulcer,Skin injuries and mechanical dermatoses,Epidermal and dermal conditions,Skin,N
132,2,Lymphoedema,Lymphoedemas,Lymphatic vessel disorders,Vasc,N
133,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
134,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
134,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
134,3,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
134,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
135,1,Biliary colic,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
135,2,Cholecystectomy,Biliary tract and gallbladder therapeutic procedures,Hepatobiliary therapeutic procedures,Surg,N
135,3,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
135,4,Insulin-like growth factor increased,Endocrine analyses and imaging NEC,Endocrine investigations (incl sex hormones),Inv,N
136,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
136,2,Amylase increased,Digestive enzymes,Gastrointestinal investigations,Inv,N
137,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
137,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
138,1,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
139,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
139,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
139,3,Retching,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
139,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
140,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
140,2,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
140,3,Thrombotic thrombocytopenic purpura,Thrombocytopenias,Platelet disorders,Blood,N
141,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
141,2,Alopecia,Alopecias,Skin appendage conditions,Skin,N
142,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
143,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
144,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
144,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
144,3,Therapeutic response delayed,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
145,1,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
146,1,Functional gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
146,2,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
146,3,Necrotising colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
147,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
148,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
149,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
150,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
150,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
150,3,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
150,4,Mucosal erosion,Mucosal findings abnormal,General system disorders NEC,Genrl,N
150,5,Parotid gland enlargement,Salivary gland enlargements,Salivary gland conditions,Gastr,N
150,6,Purulent discharge,Infections NEC,Infections - pathogen unspecified,Infec,N
150,7,Salivary gland pain,Salivary gland disorders NEC,Salivary gland conditions,Gastr,N
150,8,Staphylococcal parotitis,Staphylococcal infections,Bacterial infectious disorders,Infec,N
150,9,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
151,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
151,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
151,3,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
151,4,Mucosal erosion,Mucosal findings abnormal,General system disorders NEC,Genrl,N
151,5,Parotid gland enlargement,Salivary gland enlargements,Salivary gland conditions,Gastr,N
151,6,Purulent discharge,Infections NEC,Infections - pathogen unspecified,Infec,N
151,7,Staphylococcal parotitis,Staphylococcal infections,Bacterial infectious disorders,Infec,N
151,8,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
152,1,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
153,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
153,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
154,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
154,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
154,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
154,4,Vascular operation,Vascular therapeutic procedures NEC,Vascular therapeutic procedures,Surg,N
155,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
155,2,Energy increased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
155,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
156,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
156,2,Peroneal nerve palsy,Mononeuropathies,Peripheral neuropathies,Nerv,N
157,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
157,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
157,3,Hyperbilirubinaemia,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
158,1,Therapeutic embolisation,Vascular therapeutic procedures NEC,Vascular therapeutic procedures,Surg,N
159,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
159,2,Neuroendocrine tumour,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
160,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
160,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
161,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
162,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
163,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
163,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
163,3,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
163,4,Hyperosmolar state,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
163,5,Obstruction gastric,Gastric and pyloric stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
164,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
164,2,Lymphoma,Lymphomas unspecified NEC,Lymphomas NEC,Neopl,N
165,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
165,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
166,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
166,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
167,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
167,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
168,1,Cold sweat,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
168,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
168,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
168,4,Respiratory rate increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
168,5,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
169,1,Parotid gland enlargement,Salivary gland enlargements,Salivary gland conditions,Gastr,N
169,2,Sialoadenitis,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
170,1,Biliary colic,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
171,1,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
172,1,Biliary colic,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
173,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
174,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
174,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
174,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
174,4,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
174,5,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
174,6,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
174,7,Thyroid function test abnormal,Thyroid analyses,Endocrine investigations (incl sex hormones),Inv,N
174,8,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
175,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
176,1,Carcinoid syndrome,Ectopic endocrine disorders,Neoplastic and ectopic endocrinopathies,Endo,N
176,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
176,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
176,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
176,5,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
176,6,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
177,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
177,2,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
177,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
177,4,Headache,Headaches NEC,Headaches,Nerv,N
177,5,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
177,6,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
177,7,Vitamin B12 deficiency,Water soluble vitamin deficiencies,Vitamin related disorders,Metab,N
178,1,Postural orthostatic tachycardia syndrome,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
179,1,Bladder neoplasm,Urinary tract neoplasms unspecified malignancy NEC,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
180,1,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
181,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
182,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
183,1,Headache,Headaches NEC,Headaches,Nerv,N
183,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
183,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
183,4,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
183,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
184,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
184,2,Joint injury,Bone and joint injuries NEC,Bone and joint injuries,Inj&P,N
184,3,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
185,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
185,2,Hepatic embolisation,Arterial therapeutic procedures (excl aortic),Vascular therapeutic procedures,Surg,N
185,3,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
185,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
185,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
186,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
187,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
187,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
188,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
188,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
189,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
189,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
190,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
191,1,Carcinoid tumour,Carcinoid tumours,Endocrine neoplasms malignant and unspecified,Neopl,Y
191,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
191,3,Intestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
191,4,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
191,5,Irritable bowel syndrome,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
191,6,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
192,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
192,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
192,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
192,4,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
193,1,Respiratory arrest,Breathing abnormalities,Respiratory disorders NEC,Resp,N
194,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
194,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
195,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
196,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
196,2,Insulin-like growth factor increased,Endocrine analyses and imaging NEC,Endocrine investigations (incl sex hormones),Inv,N
197,1,Lung neoplasm malignant,Respiratory tract and pleural neoplasms malignant cell type unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
197,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
197,3,Muscle atrophy,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
197,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
198,1,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
199,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
200,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
201,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
201,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
201,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
201,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
201,5,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
202,1,Cardiac discomfort,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
202,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
202,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
202,4,Dyskinesia,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
202,5,Heart rate irregular,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
202,6,Micturition urgency,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
202,7,Ovarian cancer,Ovarian neoplasms malignant (excl germ cell),Reproductive neoplasms female malignant and unspecified,Neopl,N
202,8,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
202,9,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
202,10,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
202,11,Thirst,Feelings and sensations NEC,General system disorders NEC,Genrl,N
203,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
203,2,Respiratory arrest,Breathing abnormalities,Respiratory disorders NEC,Resp,N
204,1,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
205,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
205,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
205,3,Peritonitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
205,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
206,1,Injection site injury,Injection site reactions,Administration site reactions,Genrl,N
207,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
208,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
208,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
208,3,Intestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
209,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
210,1,Acromegaly,Anterior pituitary hyperfunction,Hypothalamus and pituitary gland disorders,Endo,N
211,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
211,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
211,3,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
211,4,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
211,5,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
212,1,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
212,2,Syringe issue,Device physical property and chemical issues,Device issues,Prod,N
213,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
214,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
214,2,Candida sepsis,Candida infections,Fungal infectious disorders,Infec,N
214,3,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
214,4,Hepatic lesion,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
215,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
216,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
216,2,Frequent bowel movements,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
217,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
217,2,Blood glucagon decreased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
217,3,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
217,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
217,5,Impaired work ability,Disability issues,Lifestyle issues,SocCi,N
217,6,Psychological factor affecting medical condition,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
217,7,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
217,8,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
218,1,Headache,Headaches NEC,Headaches,Nerv,N
219,1,Hodgkin's disease,Hodgkin's disease NEC,Lymphomas Hodgkin's disease,Neopl,N
220,1,Blood testosterone decreased,Reproductive hormone analyses,Endocrine investigations (incl sex hormones),Inv,N
220,2,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
221,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
222,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
223,1,Supraventricular tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
224,1,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
225,1,Atrioventricular block complete,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
226,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
226,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
226,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
227,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
227,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
227,3,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
228,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
229,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
229,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
230,1,Dizziness postural,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
230,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
230,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
230,4,Long QT syndrome,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
230,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
231,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
232,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
232,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
233,1,Adverse reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
233,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
234,1,Pathological fracture,Fractures NEC,Fractures,Musc,N
235,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
235,2,Muscle tightness,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
235,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
236,1,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
237,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
237,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
237,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
237,4,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
237,5,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
238,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
238,2,Femur fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
238,3,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
238,4,Pathological fracture,Fractures NEC,Fractures,Musc,N
239,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
239,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
239,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
240,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
240,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
240,3,Skin mass,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
241,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
242,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
243,1,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
244,1,Embolism,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
245,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
246,1,Blood calcium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
246,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
247,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
247,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
247,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
248,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
249,1,Blindness transient,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
250,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
250,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
250,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
251,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
251,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
251,3,Metastases to spine,Metastases to specified sites,Metastases,Neopl,N
251,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
252,1,Cholecystitis acute,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
252,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
253,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
254,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
255,1,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
255,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
255,3,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
255,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
255,5,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
255,6,Vaginal discharge,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
256,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
256,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
257,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
258,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
259,1,Headache,Headaches NEC,Headaches,Nerv,N
259,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
259,3,Restless legs syndrome,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
260,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
260,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
260,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
261,1,Apnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
261,2,Respiratory depression,Breathing abnormalities,Respiratory disorders NEC,Resp,N
262,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
263,1,Headache,Headaches NEC,Headaches,Nerv,N
263,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
263,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
264,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
264,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
265,1,Gastrointestinal stoma complication,Stoma complications,Procedural related injuries and complications NEC,Inj&P,N
265,2,Paradoxical drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
266,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
266,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
266,3,Growth hormone deficiency,Anterior pituitary hypofunction,Hypothalamus and pituitary gland disorders,Endo,N
266,4,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
267,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
267,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
267,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
268,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
269,1,Carcinoid crisis,Ectopic endocrine disorders,Neoplastic and ectopic endocrinopathies,Endo,N
269,2,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
270,1,Supraventricular tachyarrhythmia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
271,1,Cholangitis,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
271,2,Cholecystitis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
271,3,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
271,4,Gallbladder enlargement,Gallbladder disorders NEC,Gallbladder disorders,Hepat,N
271,5,Gallbladder fistula,Gallbladder disorders NEC,Gallbladder disorders,Hepat,N
271,6,Intra-abdominal fluid collection,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
272,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
273,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
273,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
274,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
275,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
275,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
276,1,Neuroendocrine tumour,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,Y
277,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
278,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
278,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
279,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
279,2,Post procedural complication,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
279,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
279,4,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
279,5,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
279,6,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
280,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
281,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
282,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
282,2,Drug-disease interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
282,3,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
283,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
283,2,Drug-disease interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
283,3,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
284,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
284,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
285,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
286,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
287,1,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
288,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
288,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
288,3,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
288,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
289,1,Hypocalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
290,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
291,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
291,2,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
292,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
293,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
294,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
294,2,Ear disorder,Ear disorders NEC,Aural disorders NEC,Ear,N
294,3,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
294,4,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
294,5,Visual field defect,Visual field disorders,Vision disorders,Eye,N
294,6,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
295,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
295,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
295,3,Faeces soft,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
295,4,Frequent bowel movements,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
296,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
297,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
298,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
298,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
298,3,General physical condition abnormal,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
298,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
299,1,Acromegaly,Anterior pituitary hyperfunction,Hypothalamus and pituitary gland disorders,Endo,N
299,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
299,3,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
299,4,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
299,5,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
299,6,Deformity,General signs and symptoms NEC,General system disorders NEC,Genrl,N
299,7,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
299,8,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
299,9,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
299,10,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
299,11,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
299,12,Osteoarthritis,Osteoarthropathies,Joint disorders,Musc,N
299,13,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
299,14,Poor quality sleep,Dyssomnias,Sleep disorders and disturbances,Psych,N
300,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
301,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
301,2,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
302,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
303,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
304,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
305,1,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
305,2,Hyperinsulinaemic hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
306,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
306,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
306,3,Whipple's disease,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
307,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
308,1,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,N
308,2,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
308,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
308,4,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
308,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
308,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
308,7,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
308,8,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
308,9,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
308,10,Musculoskeletal chest pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
308,11,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
308,12,Pathological fracture,Fractures NEC,Fractures,Musc,N
308,13,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
308,14,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
309,1,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,N
309,2,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
309,3,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
309,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
309,5,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
309,6,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
309,7,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
309,8,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
310,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
311,1,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
312,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
313,1,Carcinoid tumour,Carcinoid tumours,Endocrine neoplasms malignant and unspecified,Neopl,Y
313,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
314,1,Necrotising colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
315,1,Angina unstable,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
316,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
316,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
316,3,Diastolic dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
316,4,Headache,Headaches NEC,Headaches,Nerv,N
316,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
316,6,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
316,7,Hypogonadism,Endocrine abnormalities of gonadal function NEC,Endocrine disorders of gonadal function,Endo,N
316,8,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
316,9,IIIrd nerve paralysis,Eye movement disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
316,10,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
316,11,Obesity,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
316,12,Obstructive sleep apnoea syndrome,Breathing abnormalities,Respiratory disorders NEC,Resp,N
316,13,Osteoarthritis,Osteoarthropathies,Joint disorders,Musc,N
316,14,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
316,15,Systolic dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
316,16,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
316,17,Type 2 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
317,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
317,2,Pituitary tumour recurrent,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
318,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
319,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
320,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
320,2,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
321,1,Drug ineffective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
321,2,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
321,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
322,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
323,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
324,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
324,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
325,1,Blood glucose decreased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
325,2,Diabetes mellitus inadequate control,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
325,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
325,4,Procedural pain,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
326,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
327,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
327,2,Biliary dilatation,Structural and other bile duct disorders,Bile duct disorders,Hepat,N
327,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
327,4,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
327,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
327,6,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
327,7,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
327,8,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
327,9,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
327,10,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
327,11,Tumour marker increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
327,12,Tumour necrosis,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
327,13,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
327,14,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
328,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
329,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
329,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
329,3,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
330,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
331,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
332,1,Impaired gastric emptying,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
332,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
333,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
333,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
333,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
334,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
334,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
335,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
336,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
337,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
337,2,Insulin-like growth factor decreased,Endocrine analyses and imaging NEC,Endocrine investigations (incl sex hormones),Inv,N
338,1,Carcinoid crisis,Ectopic endocrine disorders,Neoplastic and ectopic endocrinopathies,Endo,Y
338,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
339,1,Blood catecholamines increased,Adrenal medulla tests,Endocrine investigations (incl sex hormones),Inv,N
339,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
339,3,Movement disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
339,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
339,5,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
340,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
340,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
341,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
342,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
343,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
343,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
344,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
345,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
345,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
346,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
347,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
348,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
348,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
349,1,Carcinoid syndrome,Ectopic endocrine disorders,Neoplastic and ectopic endocrinopathies,Endo,N
350,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
351,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
351,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
352,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
352,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
353,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
353,2,Gastroenteritis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
353,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
353,4,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
354,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
355,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
356,1,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
356,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
356,3,Ear infection,Ear infections,Infections - pathogen unspecified,Infec,N
356,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
356,5,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
356,6,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
356,7,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
356,8,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
356,9,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
357,1,Carcinoid heart disease,Cardiac valve disorders NEC,Cardiac valve disorders,Card,N
357,2,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
357,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
357,4,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
358,1,Carcinoid crisis,Ectopic endocrine disorders,Neoplastic and ectopic endocrinopathies,Endo,N
358,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
358,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
358,4,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
358,5,Movement disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
358,6,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
358,7,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
359,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
360,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
360,2,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
360,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
361,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
361,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
362,1,Recurrent cancer,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
362,2,Urine analysis abnormal,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
363,1,Glycosylated haemoglobin increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
363,2,Tooth infection,Dental and oral soft tissue infections,Infections - pathogen unspecified,Infec,N
363,3,Type 2 diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
364,1,Cachexia,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
365,1,Carcinoid crisis,Ectopic endocrine disorders,Neoplastic and ectopic endocrinopathies,Endo,N
365,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
365,3,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
365,4,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
365,5,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
366,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
367,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
367,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
367,3,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
368,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
369,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
369,2,Volvulus,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
370,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
371,1,Hepatic lesion,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
371,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
372,1,Central nervous system lesion,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
372,2,Multiple sclerosis relapse,Multiple sclerosis acute and progressive,Demyelinating disorders,Nerv,N
373,1,Inflammation,Inflammations,General system disorders NEC,Genrl,N
373,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
373,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
374,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
374,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
374,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
374,4,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
375,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
375,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
376,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
376,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
376,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
376,4,Paracentesis,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
376,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
376,6,Thoracic cavity drainage,Chest wall and mediastinal therapeutic procedures,Respiratory tract therapeutic procedures,Surg,N
377,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
377,2,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
378,1,Adenoma benign,Neoplasms benign site unspecified NEC,Miscellaneous and site unspecified neoplasms benign,Neopl,N
378,2,Headache,Headaches NEC,Headaches,Nerv,N
378,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
379,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
379,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
380,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
380,2,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
380,3,Benign hepatic neoplasm,Hepatobiliary neoplasms benign,Hepatic and biliary neoplasms benign,Neopl,N
380,4,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
380,5,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
380,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
380,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
381,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
382,1,Blood pressure systolic increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
382,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
383,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
384,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
385,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
385,2,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
386,1,Glomerular filtration rate abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
386,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
387,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
387,2,Blood chromogranin A increased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
387,3,Candida infection,Candida infections,Fungal infectious disorders,Infec,N
387,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
387,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
387,6,Parathyroid hormone-related protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
387,7,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
388,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
388,2,Bleeding varicose vein,Varicose veins NEC,Venous varices,Vasc,N
388,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
388,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
388,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
388,6,Neuroendocrine tumour,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
388,7,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
388,8,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
388,9,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
389,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
390,1,Parotid gland enlargement,Salivary gland enlargements,Salivary gland conditions,Gastr,N
391,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
392,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
392,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
392,3,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
392,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
392,5,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
392,6,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
392,7,Haemorrhoids,Haemorrhoids and gastrointestinal varices (excl oesophageal),Gastrointestinal vascular conditions,Gastr,N
392,8,Headache,Headaches NEC,Headaches,Nerv,N
392,9,Heart sounds abnormal,Cardiac auscultatory investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
392,10,Helicobacter infection,Helicobacter infections,Bacterial infectious disorders,Infec,N
392,11,Inflammation,Inflammations,General system disorders NEC,Genrl,N
392,12,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
392,13,Musculoskeletal chest pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
392,14,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
392,15,Nervousness,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
392,16,Neuralgia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
392,17,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
392,18,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
392,19,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
392,20,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
392,21,Sinus disorder,Paranasal sinus disorders (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
392,22,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
393,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
393,2,Metastases to ovary,Metastases to specified sites,Metastases,Neopl,N
394,1,Carcinoid syndrome,Ectopic endocrine disorders,Neoplastic and ectopic endocrinopathies,Endo,N
394,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
394,3,Neuroendocrine tumour,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
395,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
395,2,Nephrolithiasis,Renal lithiasis,Urolithiases,Renal,N
396,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
396,2,Drug tolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
397,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
398,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
399,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
399,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
399,3,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
400,1,Cholecystitis acute,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
400,2,Cholecystitis acute,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
400,3,Hepatic artery embolism,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
400,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
400,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
400,6,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
400,7,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
400,8,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
400,9,Tricuspid valve incompetence,Tricuspid valvular disorders,Cardiac valve disorders,Card,N
401,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
401,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
402,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
402,2,Biliary colic,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
402,3,Sphincter of Oddi dysfunction,Obstructive bile duct disorders (excl neoplasms),Bile duct disorders,Hepat,N
403,1,Cervix carcinoma,Cervix neoplasms malignant,Reproductive neoplasms female malignant and unspecified,Neopl,N
403,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
404,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
405,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
406,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
406,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
407,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
407,2,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
408,1,Transaminases increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
409,1,Pancreatic failure,Pancreatic disorders NEC,Exocrine pancreas conditions,Gastr,N
409,2,Steatorrhoea,Malabsorption syndromes,Malabsorption conditions,Gastr,N
410,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
410,2,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
410,3,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
410,4,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
410,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
410,6,Frequent bowel movements,Gastrointestinal spastic and hypermotility disorders,Gastrointestinal motility and defaecation conditions,Gastr,N
410,7,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
410,8,Product preparation issue,Product preparation errors and issues,Medication errors and other product use errors and issues,Inj&P,N
410,9,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
411,1,Anger,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
411,2,Blood glucose fluctuation,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
411,3,Bursitis,Bursal disorders,Synovial and bursal disorders,Musc,N
411,4,Concomitant disease aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
411,5,Deafness unilateral,Hearing losses,Hearing disorders,Ear,N
411,6,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
411,7,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
411,8,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
411,9,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
411,10,Nerve compression,Mononeuropathies,Peripheral neuropathies,Nerv,N
411,11,Neuralgia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
411,12,Oral mucosal eruption,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
411,13,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
411,14,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
411,15,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
411,16,Rhinitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
411,17,Rhinorrhoea,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
411,18,Sensory loss,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
411,19,Steatorrhoea,Malabsorption syndromes,Malabsorption conditions,Gastr,N
411,20,Synovial cyst,Synovial disorders,Synovial and bursal disorders,Musc,N
412,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
412,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
412,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
412,4,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
413,1,Blood folate decreased,Vitamin analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
413,2,Crohn's disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
413,3,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
414,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
414,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
414,3,Hepatic pain,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
414,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
414,5,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
414,6,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
415,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
415,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
415,3,Metastasis,Metastases to unknown and unspecified sites,Metastases,Neopl,N
415,4,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
415,5,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
416,1,Gastroenteropancreatic neuroendocrine tumour disease,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
416,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
416,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
416,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
417,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
417,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
417,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
417,4,Pancreatic polypeptide level decreased,"Gastrointestinal, pancreatic and APUD hormone analyses",Endocrine investigations (incl sex hormones),Inv,N
417,5,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
417,6,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
418,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
418,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
418,3,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
419,1,Carcinoid heart disease,Cardiac valve disorders NEC,Cardiac valve disorders,Card,N
419,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
419,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
419,4,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
419,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
419,6,Tricuspid valve incompetence,Tricuspid valvular disorders,Cardiac valve disorders,Card,N
420,1,Coronavirus infection,Coronavirus infections,Viral infectious disorders,Infec,N
420,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
421,1,Adrenocortical insufficiency acute,Adrenal cortical hypofunctions,Adrenal gland disorders,Endo,N
421,2,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
421,3,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
421,4,Drug ineffective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
421,5,Emotional distress,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
421,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
421,7,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
421,8,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
421,9,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
421,10,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
421,11,Premature menopause,Menopausal effects NEC,Menopause related conditions,Repro,N
421,12,Temperature regulation disorder,Body temperature altered,Body temperature conditions,Genrl,N
422,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
422,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
422,3,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
422,4,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
422,5,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
422,6,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
422,7,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
422,8,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
422,9,Pituitary tumour,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
422,10,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
423,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
424,1,Diabetes insipidus,Posterior pituitary disorders,Hypothalamus and pituitary gland disorders,Endo,N
424,2,Headache,Headaches NEC,Headaches,Nerv,N
424,3,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
425,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
425,2,Incorrect dosage administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
425,3,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
426,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
427,1,Chest injury,Chest and respiratory tract injuries NEC,Injuries NEC,Inj&P,N
427,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
427,3,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
427,4,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
427,5,Pleuritic pain,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
427,6,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
428,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
428,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
429,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
430,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
431,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
432,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
432,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
432,3,Fluid retention,Total fluid volume increased,Electrolyte and fluid balance conditions,Metab,N
432,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
432,5,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
433,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
433,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
434,1,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
434,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
434,3,Toxic shock syndrome,Infections NEC,Infections - pathogen unspecified,Infec,N
435,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
435,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
436,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
436,2,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
436,3,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
437,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
437,2,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
437,3,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
437,4,Biliary obstruction,Obstructive bile duct disorders (excl neoplasms),Bile duct disorders,Hepat,N
437,5,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
437,6,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
437,7,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
437,8,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
437,9,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
437,10,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
437,11,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
437,12,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
437,13,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
437,14,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
437,15,Limb discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
437,16,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
437,17,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
437,18,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
437,19,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
437,20,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
437,21,Musculoskeletal discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
437,22,Neuroendocrine tumour,Endocrine neoplasms malignant and unspecified NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
437,23,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
437,24,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
437,25,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
437,26,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
438,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
438,2,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
438,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
438,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
439,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
440,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
440,2,Nephrolithiasis,Renal lithiasis,Urolithiases,Renal,N
441,1,Hepatic neoplasm,Hepatobiliary neoplasms malignancy unspecified,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
441,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
441,3,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
442,1,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
442,2,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
443,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
444,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
444,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
444,3,Malnutrition,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
445,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
445,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
445,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
446,1,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
446,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
447,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
448,1,Headache,Headaches NEC,Headaches,Nerv,N
448,2,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
449,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
449,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
449,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
450,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
451,1,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
451,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
452,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
453,1,Headache,Headaches NEC,Headaches,Nerv,N
453,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
454,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
454,2,Headache,Headaches NEC,Headaches,Nerv,N
454,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
455,1,Headache,Headaches NEC,Headaches,Nerv,N
455,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
456,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
456,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
456,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
457,1,Food poisoning,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
458,1,Body temperature,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
458,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
458,3,Ear infection,Ear infections,Infections - pathogen unspecified,Infec,N
459,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
460,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
460,2,Blood testosterone increased,Reproductive hormone analyses,Endocrine investigations (incl sex hormones),Inv,N
460,3,Cortisol increased,Adrenal cortex tests,Endocrine investigations (incl sex hormones),Inv,N
460,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
460,5,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
460,6,Headache,Headaches NEC,Headaches,Nerv,N
460,7,Hirsutism,Hypertrichoses,Skin appendage conditions,Skin,N
460,8,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
460,9,Insulin-like growth factor increased,Endocrine analyses and imaging NEC,Endocrine investigations (incl sex hormones),Inv,N
461,1,Headache,Headaches NEC,Headaches,Nerv,N
461,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
462,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
462,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
462,3,Skin infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
462,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
463,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
464,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
464,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
465,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
465,2,Therapeutic response unexpected,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
466,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
467,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
467,2,Product preparation error,Product preparation errors and issues,Medication errors and other product use errors and issues,Inj&P,N
468,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
468,2,Hyperplasia,Trophic disorders,Tissue disorders NEC,Genrl,N
469,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
469,2,Sleep apnoea syndrome,Breathing abnormalities,Respiratory disorders NEC,Resp,N
469,3,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
470,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
471,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
471,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
472,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
472,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
473,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
474,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
475,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
476,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
476,2,Headache,Headaches NEC,Headaches,Nerv,N
476,3,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
477,1,Cardiac valve disease,Cardiac valve disorders NEC,Cardiac valve disorders,Card,N
477,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
477,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
478,1,5-hydroxyindolacetic acid,Metabolism tests NEC,"Metabolic, nutritional and blood gas investigations",Inv,N
479,1,Cardiac valve disease,Cardiac valve disorders NEC,Cardiac valve disorders,Card,N
479,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
479,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
480,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
480,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
481,1,Cholecystitis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
481,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
482,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
482,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
483,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
483,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
483,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
483,4,Sciatica,Lumbar spinal cord and nerve root disorders,Spinal cord and nerve root disorders,Nerv,N
483,5,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
484,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
485,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
486,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
486,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
486,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
487,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
488,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
489,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
489,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
490,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
491,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
492,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
492,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
493,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
493,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
494,1,Headache,Headaches NEC,Headaches,Nerv,N
495,1,Administration site infection,Infections NEC,Infections - pathogen unspecified,Infec,N
496,1,Administration site mass,Administration site reactions NEC,Administration site reactions,Genrl,N
496,2,Administration site pain,Administration site reactions NEC,Administration site reactions,Genrl,N
497,1,Administration site swelling,Administration site reactions NEC,Administration site reactions,Genrl,N
498,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
499,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
500,1,Brain fog,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
500,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
500,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
500,4,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
500,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
500,6,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
501,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
501,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
501,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
501,4,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
501,5,Muscle twitching,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
502,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
503,1,Musculoskeletal pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
503,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
504,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
504,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
504,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
505,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
506,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
506,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
507,1,Headache,Headaches NEC,Headaches,Nerv,N
508,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
508,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
509,1,Brain fog,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
509,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
509,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
509,4,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
509,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
510,1,Mass,Mass conditions NEC,Tissue disorders NEC,Genrl,N
511,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
511,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
511,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
512,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
513,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
514,1,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
515,1,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
516,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
517,1,Rhinorrhoea,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
518,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
519,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
519,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
519,3,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
520,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
520,2,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
520,3,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
520,4,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
520,5,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
521,1,Heart valve incompetence,Cardiac valve disorders NEC,Cardiac valve disorders,Card,N
522,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
523,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
523,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
523,3,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
524,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
524,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
524,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
524,4,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
524,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
524,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
525,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
525,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
525,3,Poor quality sleep,Dyssomnias,Sleep disorders and disturbances,Psych,N
525,4,Sitting disability,Disability issues,Lifestyle issues,SocCi,N
526,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
526,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
527,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
528,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
528,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
528,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
529,1,Erectile dysfunction,Erection and ejaculation conditions and disorders,Sexual function and fertility disorders,Repro,N
530,1,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
531,1,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
532,1,Encephalopathy,Encephalopathies NEC,Encephalopathies,Nerv,N
532,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
532,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
533,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
534,1,Encephalopathy,Encephalopathies NEC,Encephalopathies,Nerv,N
534,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
534,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
535,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
535,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
535,3,Sciatica,Lumbar spinal cord and nerve root disorders,Spinal cord and nerve root disorders,Nerv,N
536,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
537,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
538,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
538,2,Device placement issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
538,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
538,4,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
539,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
539,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
539,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
539,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
540,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
540,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
540,3,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
540,4,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
540,5,Iron deficiency anaemia,Anaemia deficiencies,Anaemias nonhaemolytic and marrow depression,Blood,N
540,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
540,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
540,8,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
541,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
542,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
542,2,Vipoma,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
543,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
543,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
543,3,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
544,1,Exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
544,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
545,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
546,1,Postprandial hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
546,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
546,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
546,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
547,1,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
547,2,Sickle cell anaemia with crisis,Sickle cell trait and disorders,Haemoglobinopathies,Blood,N
548,1,Headache,Headaches NEC,Headaches,Nerv,N
549,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
549,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
549,3,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
549,4,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
550,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
550,2,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
550,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
550,4,Gastrointestinal stoma complication,Stoma complications,Procedural related injuries and complications NEC,Inj&P,N
550,5,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
550,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
550,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
550,8,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
551,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
551,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
552,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
552,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
552,3,Injection site discomfort,Injection site reactions,Administration site reactions,Genrl,N
552,4,Injection site hypoaesthesia,Injection site reactions,Administration site reactions,Genrl,N
552,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
552,6,Sleep disorder,Sleep disorders NEC,Sleep disorders and disturbances,Psych,N
552,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
553,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
554,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
554,2,Injection site hypoaesthesia,Injection site reactions,Administration site reactions,Genrl,N
554,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
555,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
555,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
555,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
555,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
555,5,Small intestine neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
555,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
556,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
556,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
556,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
556,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
556,5,Malnutrition,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
556,6,Pancreatic carcinoma metastatic,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
556,7,Performance status decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
556,8,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
556,9,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
557,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
557,2,Headache,Headaches NEC,Headaches,Nerv,N
557,3,Hepatic pain,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
557,4,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
557,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
557,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
557,7,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
557,8,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
557,9,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
558,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
558,2,Drug dependence,Substance related and addictive disorders,Psychiatric disorders NEC,Psych,N
558,3,Encephalitis,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
558,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
558,5,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
558,6,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
558,7,Liver abscess,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,N
558,8,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
558,9,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
558,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
558,11,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
558,12,Performance status decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
558,13,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
558,14,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
559,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
559,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
559,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
559,4,Pancreatic neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
559,5,Therapy partial responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
560,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
560,2,Carcinoid heart disease,Cardiac valve disorders NEC,Cardiac valve disorders,Card,N
560,3,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
560,4,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
560,5,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
560,6,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
560,7,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
560,8,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
560,9,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
560,10,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
560,11,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
560,12,Neck pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
560,13,Small intestine neuroendocrine tumour,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
560,14,Tricuspid valve incompetence,Tricuspid valvular disorders,Cardiac valve disorders,Card,N
561,1,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
562,1,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
562,2,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
563,1,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
564,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
564,2,Headache,Headaches NEC,Headaches,Nerv,N
564,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
564,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
565,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
565,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
565,3,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
566,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
566,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
566,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
566,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
566,5,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
566,6,Headache,Headaches NEC,Headaches,Nerv,N
567,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
567,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
567,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
567,4,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
567,5,Syringe issue,Device physical property and chemical issues,Device issues,Prod,N
567,6,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
567,7,Wrong technique in device usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
568,1,Bacterial sepsis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
568,2,Candida sepsis,Candida infections,Fungal infectious disorders,Infec,N
568,3,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
568,4,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
568,5,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
569,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
569,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
569,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
570,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
570,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
570,3,Incorrect dose administered by device,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
570,4,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
570,5,Product deposit,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
571,1,Injection related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
571,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
572,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
573,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
573,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
573,3,Hypoglycaemic seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
573,4,Insulinoma,Islet cell neoplasms and APUDoma NEC,Endocrine neoplasms malignant and unspecified,Neopl,N
573,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
573,6,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
573,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
574,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
574,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
575,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
576,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
577,1,Adverse reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
577,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
577,3,Cerebrospinal fluid leakage,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
577,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
577,5,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
577,6,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
577,7,Metastases to spine,Metastases to specified sites,Metastases,Neopl,N
577,8,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
577,9,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
577,10,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
577,11,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
578,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
578,2,Product availability issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
579,1,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
580,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
580,2,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
581,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
581,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
582,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
582,2,Product packaging difficult to open,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
583,1,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
583,2,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
